ゲノミクスにおける人工知能市場：提供（ソフトウェア＆サービス）、技術（機械学習）、機能（遺伝子配列、遺伝子編集）、用途（診断、創薬）、エンドユーザー（製薬、病院）別 - 2028年までの世界予測

Artificial Intelligence In Genomics Market by Offering (Software & Services), Technology (Machine Learning), Functionality (Gene Sequencing, Gene Editing), Application (Diagnostics, Drug discovery), End User (Pharma, Hospitals) - Global Forecasts to 2028

ゲノミクスにおける人工知能（AI）市場は、2023年の推定5億米ドルから2028年には20億米ドルへと、予測期間中に32.3%のCAGRで成長すると予測されています。同市場は、プロセスやタイムラインの迅速化、創薬・薬剤... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年5月11日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	240	270	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

ゲノミクスにおける人工知能（AI）市場は、2023年の推定5億米ドルから2028年には20億米ドルへと、予測期間中に32.3%のCAGRで成長すると予測されています。同市場は、プロセスやタイムラインの迅速化、創薬・薬剤開発の短縮化などのニーズや、コンピューティング能力の向上、ハードウェアコストの低下などの要因から、有望な成長ポテンシャルを有しています。しかし、キュレーションされたゲノムデータの不足やデータプライバシーに関する懸念が、この市場の成長を一定程度制限すると予想されます。

"ディープラーニング "はゲノミクスにおける人工知能（AI）市場の機械学習で最も成長が早いセグメント（タイプ別）"
感染症監視サービス市場では、予測期間中、ディープラーニングセグメントが最も速い成長を遂げると予想されています。ディープラーニング手法は、ゲノミクスにおける計算モデリング戦略を支配しており、DNA配列からのタンパク質結合の理解、エピジェネティック修飾、エピジェネティックマークからの遺伝子発現予測、単一細胞のメチル化状態の予測など、さまざまな問題に対処するために使用されている。ゲノムシーケンス解析ワークフローの加速化に対する需要の高まりと、遺伝子編集ツールの機能向上に対するニーズが、市場の成長を促進すると予想されます。

"ゲノムシーケンス分野は、予測期間中、機能別で最大のゲノミクスにおける人工知能（AI）市場になると予測される"
機能性に基づいて、市場はゲノムシーケンス、遺伝子編集、臨床ワークフロー、予測的遺伝子検査・予防医学に区分されます。ゲノミクスにおける人工知能（AI）市場では、ゲノムシーケンスセグメントが最大のシェアを占めています。このセグメントの大きなシェアは、染色体障害、異形症候群、催奇形性障害、単一遺伝子障害の特定にAIソリューションが使用されていることに起因すると考えられる。

"予測期間中、ゲノミクスにおける人工知能（AI）市場で欧州が2番目に大きなシェアを占めている"
予測期間中、欧州はゲノミクスにおける人工知能（AI）市場で2番目に大きなシェアを占めました。市場成長の主な促進要因は、ゲノム研究や創薬におけるAIベースのツールの採用の増加、政府の有利な取り組み、EMRの採用拡大、患者データ量の増加、ベンチャーキャピタルからの資金調達の増加、医療費の増加、老年人口の増加です。さらに、研究開発活動を進める上でのAIの可能性も、この分野に注目されています。

主な参加者の内訳は、以下の通りです：
- 企業タイプ別：Tier 1-40%, Tier 2-35%, Tier 3-25
- 役職別 - Cレベル-35％、ディレクターレベル-25％、その他-40
- 地域別：北米-45％、欧州-30％、アジア太平洋-20％、その他-5

ゲノミクスにおける人工知能（AI）市場の主要企業
ゲノミクスにおける人工知能（AI）市場で事業を展開する主なプレーヤーは、NVIDIA Corporation（米国）、Microsoft Corporation（米国）、Google, Inc.（米国）、Intel Corporation（米国）、BenevolentAI（英国）、SOPHiA GENETICS（スイス）、イルミナ社（米国）、Predictive Oncology, Inc.（米国）、Invitae Corporation（米国）、ディープゲノミクス社（カナダ）、Fabric Genomics, Inc.(米国）、Verge Genomics（米国）、Freenome Holdings, Inc.（米国）、MolecularMatch, Inc.（米国）、Dante labs（米国）、Data4Cure（米国）、PrecisionLife Ltd（英国）、Genoox（米国）、Lifebit（英国）、FDNA, Inc.(米国）、DNAnexus（米国）、Engine Biosciences（米国）、Tempus Labs, Inc（米国）、Congenica Ltd（英国）、Emedgene, Inc（米国）、Seragon Pharmaceuticals, Inc（米国）。
調査範囲です：
当レポートでは、ゲノミクスにおける人工知能（AI）市場を分析し、提供、技術、機能、用途、エンドユーザー、地域などの様々なセグメントに基づいて、この市場の市場規模および将来の成長可能性を推定することを目的としています。また、市場で入手可能な様々なゲノミクスにおける人工知能（AI）製品＆サービスの製品ポートフォリオマトリックスも掲載しています。また、本市場の主要企業の競合分析も行っており、企業プロファイル、製品提供、主要な市場戦略も併せて掲載しています。
本レポートを購入する理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握し、より大きなシェアを獲得するのに役立つと思われます。本レポートを購入された企業は、以下の戦略の1つまたは任意の組み合わせを使用して、市場での地位を強化することができます。

本レポートでは、以下のポイントについて考察しています：
- 市場浸透度：市場浸透度：世界のゲノミクスにおける人工知能（AI）市場の上位企業が提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場を製品＆サービス別、エンドユーザー別に分析しています。
- 製品の強化/革新：世界のゲノミクスにおける人工知能（AI）市場における今後の動向と製品発表に関する詳細な知見
- 市場の発展：製品＆サービス別、エンドユーザー別の有利な新興市場に関する包括的な情報
- 市場の多様化：ゲノミクス分野における人工知能（AI）の世界市場における新製品や製品強化、成長地域、最近の開発、投資に関する詳細な情報
- 競争力のある評価：世界の人工知能（AI）ゲノミクス市場における主要企業の市場シェア、成長戦略、製品提供、競合のリーダーシップマッピング、能力に関する詳細な評価。

ページTOPに戻る

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 INCLUSIONS AND EXCLUSIONS 33
1.4 STUDY SCOPE 34
1.4.1 MARKETS COVERED 34
FIGURE 1 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SEGMENTATION 34
1.4.2 REGIONS COVERED 34
1.5 YEARS CONSIDERED 35
1.6 CURRENCY CONSIDERED 36
TABLE 1 CURRENCY CONVERSION RATES 36
1.7 LIMITATIONS 36
1.8 STAKEHOLDERS 37
1.9 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
FIGURE 2 RESEARCH DESIGN 40
FIGURE 3 RESEARCH APPROACH 41
2.1.1 SECONDARY RESEARCH 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY RESEARCH 43
2.1.2.1 Key primary sources 44
2.1.2.2 Key data from primary sources 45
2.1.2.3 Key industry insights 45
2.1.2.4 Breakdown of primary interviews 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 46
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 46
2.2 MARKET SIZE ESTIMATION 46
FIGURE 6 KEY METRICS FOR ASSESSING SUPPLY OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET 47
FIGURE 7 REVENUES GENERATED BY COMPANIES FROM SALE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS SOLUTIONS 48
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION 49
FIGURE 9 BOTTOM-UP APPROACH 50
FIGURE 10 ESTIMATION OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SIZE BASED ON ADOPTION 50
FIGURE 11 TOP-DOWN APPROACH 51
TABLE 2 FACTOR ANALYSIS 52
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 52
FIGURE 12 DATA TRIANGULATION METHODOLOGY 53
2.4 RESEARCH ASSUMPTIONS 54
FIGURE 13 ASSUMPTIONS FOR RESEARCH STUDY 54
2.5 IMPACT OF RECESSION 55
2.6 RISK ASSESSMENT 55
TABLE 3 LIMITATIONS AND ASSOCIATED RISKS 55
2.7 RESEARCH LIMITATIONS 56
3 EXECUTIVE SUMMARY 57
FIGURE 14 SOFTWARE SEGMENT TO LEAD ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING 57
FIGURE 15 MACHINE LEARNING CONTINUES TO ACQUIRE LARGEST SIZE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY 58
FIGURE 16 DEEP LEARNING TO BE FASTEST-GROWING SEGMENT OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING 58
FIGURE 17 GENOME SEQUENCING TO REGISTER HIGHEST CAGR IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY 59
FIGURE 18 DIAGNOSTICS TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION 60
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SECURE LEADING POSITION IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER 60
FIGURE 20 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION 61
4 PREMIUM INSIGHTS 62
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET 62
FIGURE 21 INCREASING ADOPTION OF ARTIFICIAL INTELLIGENCE (AI) SOLUTIONS FOR DRUG DISCOVERY & DEVELOPMENT AND PRECISION MEDICINE TO DRIVE MARKET 62
4.2 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION 63
FIGURE 22 NORTH AMERICA TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET DURING FORECAST PERIOD 63
4.3 NORTH AMERICAN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER AND COUNTRY, 2022 64
FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US DOMINATED MARKET IN NORTH AMERICA IN 2022 64
4.4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING 65
FIGURE 24 SOFTWARE SEGMENT TO HOLD MAJORITY MARKET SHARE IN 2028 65
4.5 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY 65
FIGURE 25 MACHINE LEARNING TO SURPASS OTHER TECHNOLOGIES IN 2028 65
4.6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER 66
FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028 66
4.7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY 66
FIGURE 27 GENOME SEQUENCING TO BE FASTEST-GROWING SEGMENT DURING FORECAST PERIOD 66
4.8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION 67
FIGURE 28 DIAGNOSTICS TO DOMINATE MARKET IN 2028 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
5.2.1 DRIVERS 69
5.2.1.1 Need to accelerate processes and timeline and reduce drug development & discovery costs 69
5.2.1.2 Increased partnerships and collaborations among players and growing investments in AI in genomics 69
5.2.1.3 Rising adoption of AI in precision medicine 70
5.2.1.4 Explosion in bioinformatics data and genomic datasets 70
FIGURE 29 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023 71
5.2.1.5 Improving computing power and declining hardware cost 71
5.2.2 RESTRAINTS 72
5.2.2.1 Lack of skilled AI workforce and ambiguous regulatory guidelines for medical software 72
5.2.3 OPPORTUNITIES 72
5.2.3.1 Focus on developing human-aware AI systems 72
5.2.4 CHALLENGES 73
5.2.4.1 Lack of curated genomic data 73
5.2.4.2 Data privacy concerns 73
FIGURE 30 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2019–2021 73
5.3 ECOSYSTEM ANALYSIS 74
FIGURE 31 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: ECOSYSTEM ANALYSIS 74
6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING 75
6.1 INTRODUCTION 76
FIGURE 32 SOFTWARE SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022 76
TABLE 4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 76
6.2 SOFTWARE 77
6.2.1 INTELLIGENT SOFTWARE TO REDUCE ERRORS CAUSED BY STANDARD STATISTICAL APPROACHES 77
TABLE 5 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 6 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 7 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 78
6.3 SERVICES 78
6.3.1 RISING AI TECHNOLOGY ADOPTION IN VARIOUS END-USE INDUSTRIES TO BOOST MARKET 78
TABLE 8 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 79
TABLE 9 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 10 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 79
7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY 80
7.1 INTRODUCTION 81
FIGURE 33 MACHINE LEARNING SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022 81
TABLE 11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 81
7.2 MACHINE LEARNING 82
FIGURE 34 DEEP LEARNING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 82
TABLE 12 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 83
TABLE 13 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 14 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 15 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 84
7.2.1 DEEP LEARNING 84
7.2.1.1 Growing demand for accelerated genome sequencing analysis workflows and improved function of gene editing tools to propel market 84
TABLE 16 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 17 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 18 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 85
7.2.2 SUPERVISED LEARNING 86
7.2.2.1 To help create predictive models for population health management 86
TABLE 19 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 20 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 21 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 87
7.2.3 REINFORCEMENT LEARNING 87
7.2.3.1 Need to reduce costs associated with collecting labeled training data to drive segment 87
TABLE 22 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 23 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 24 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 88
7.2.4 UNSUPERVISED LEARNING 89
7.2.4.1 Ability to perform more complex processing tasks than supervised learning systems to drive market 89
TABLE 25 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 26 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 27 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 90
TABLE 28 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 90
TABLE 29 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 30 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 91
7.3 OTHER TECHNOLOGIES 91
TABLE 31 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 32 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 33 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 92
8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY 93
8.1 INTRODUCTION 94
FIGURE 35 GENOME SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 94
TABLE 34 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 94
8.2 GENOME SEQUENCING 95
8.2.1 INCREASING ADOPTION OF MACHINE AND DEEP LEARNING IN DIAGNOSTICS AND DRUG DISCOVERY PROCESSES TO ENHANCE MARKET GROWTH 95
TABLE 35 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 36 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 37 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 96
8.3 GENE EDITING 96
8.3.1 TO HELP IMPROVE GENE EDITING FUNCTIONS AND REDUCE TIME AND COSTS 96
TABLE 38 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 39 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 40 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 98
8.4 CLINICAL WORKFLOW 98
8.4.1 TO HELP INCREASE EFFICIENCY OF CLINICAL WORKFLOWS 98
TABLE 41 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 42 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 43 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 99
8.5 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE 99
8.5.1 AI IN GENOMICS TO PREDICT OUTCOMES AND RISKS ASSOCIATED WITH CURING GENETIC DISEASES BASED ON AVAILABLE DATA 99
TABLE 44 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 45 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 46 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 100
9 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION 101
9.1 INTRODUCTION 102
FIGURE 36 DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 102
TABLE 47 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
9.2 DIAGNOSTICS 103
9.2.1 AI IN GENOMICS FOR DIAGNOSTICS TO HELP IDENTIFY CHROMOSOMAL DISORDERS, DYSMORPHIC SYNDROMES, TERATOGENIC DISORDERS, AND SINGLE-GENE DISORDERS 103
TABLE 48 INDICATIVE LIST OF DEVELOPMENTS FOR DIAGNOSTICS APPLICATION 104
TABLE 49 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 50 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 51 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 105
9.3 DRUG DISCOVERY & DEVELOPMENT 105
9.3.1 GROWING APPLICATION OF AI IN GENOMICS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 105
TABLE 52 INDICATIVE LIST OF DEVELOPMENTS FOR DRUG DELIVERY & DISCOVERY APPLICATION 106
TABLE 53 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 54 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 55 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 107
9.4 PRECISION MEDICINE 107
9.4.1 FOCUSE ON IDENTIFYING EFFECTIVE MEDICAL TREATMENTS FOR PATIENTS TO DRIVE MARKET 107
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS FOR PRECISION MEDICINE APPLICATION 108
TABLE 57 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 58 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 59 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 109
9.5 AGRICULTURE & ANIMAL RESEARCH 109
9.5.1 AI IN GENOMICS TO HELP IMPROVE CROP AND LIVESTOCK PRODUCTIVITY 109
TABLE 60 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 61 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 62 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 111
9.6 OTHER APPLICATIONS 111
TABLE 63 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 64 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 65 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 112
10 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER 113
10.1 INTRODUCTION 114
FIGURE 37 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 114
TABLE 66 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 114
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 115
10.2.1 RISING DEMAND FOR SOLUTIONS TO REDUCE TIME AND COSTS OF DRUG DEVELOPMENT 115
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: INDICATIVE DEVELOPMENTS 115
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 116
10.3 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS 117
10.3.1 INCREASED RESEARCH ACTIVITIES TO ENCOURAGE USE OF AI IN GENOMICS IN ACADEMIC AND GOVERNMENT INSTITUTES 117
TABLE 71 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: INDICATIVE DEVELOPMENTS 117
TABLE 72 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 73 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 74 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 118
10.4 HOSPITALS & HEALTHCARE PROVIDERS 118
10.4.1 GROWING DEMAND FOR PHARMACOGENOMICS TO PROPEL ACCEPTANCE OF NGS IN HOSPITALS 118
TABLE 75 HOSPITALS & HEALTHCARE PROVIDERS: INDICATIVE DEVELOPMENTS 119
TABLE 76 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 77 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 78 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 120
10.5 OTHER END USERS 120
TABLE 79 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 80 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 81 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 121
11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION 122
11.1 INTRODUCTION 123
FIGURE 38 ASIA PACIFIC TO EMERGE AS NEW HOTSPOT DURING FORECAST PERIOD 123
FIGURE 39 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 123
TABLE 82 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 124
11.2 NORTH AMERICA 124
11.2.1 NORTH AMERICA: RECESSION IMPACT 124
FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT 125
TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 126
TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 127
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 128
11.2.2 US 128
11.2.2.1 Initiatives to accelerate genomic research and growing adoption of AI to bolster market 128
TABLE 90 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 130
TABLE 91 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130
TABLE 92 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 93 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 131
TABLE 94 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 95 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 132
11.2.3 CANADA 132
11.2.3.1 Increasing research in genomics to drive market 132
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 133
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 134
TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 135
11.3 EUROPE 135
11.3.1 EUROPE: RECESSION IMPACT 135
TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 136
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 137
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 138
11.3.2 UK 138
11.3.2.1 Adoption of AI in genomics for drug discovery to fuel market 138
TABLE 109 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 140
TABLE 110 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 111 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 112 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 141
TABLE 113 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 114 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 142
11.3.3 GERMANY 142
11.3.3.1 Availability of funding for AI initiatives to boost market 142
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 143
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 144
TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 145
11.3.4 FRANCE 145
11.3.4.1 Increasing government investments in NGS to boost market 145
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 146
TABLE 122 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 123 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 147
TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 148
11.3.5 REST OF EUROPE 148
TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 149
TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 150
TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 151
11.4 ASIA PACIFIC 151
11.4.1 ASIA PACIFIC: RECESSION IMPACT 152
FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT 153
TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 154
TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154
TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 155
TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
11.5 REST OF THE WORLD 156
11.5.1 REST OF THE WORLD: RECESSION IMPACT 157
TABLE 139 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 158
TABLE 140 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 158
TABLE 141 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 142 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 159
TABLE 143 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 144 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 160
12 COMPETITIVE LANDSCAPE 161
12.1 OVERVIEW 161
12.2 KEY MARKET PLAYERS’ STRATEGIES/RIGHT TO WIN 161
TABLE 145 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET 161
FIGURE 42 KEY DEVELOPMENTS BY MAJOR MARKET PLAYERS BETWEEN JANUARY 2020 AND MARCH 2023 163
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS, 2022 164
FIGURE 43 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS, 2022 164
12.4 MARKET RANKING ANALYSIS, 2022 164
FIGURE 44 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SHARE ANALYSIS, 2022 165
12.5 COMPETITIVE BENCHMARKING 167
TABLE 146 COMPANY FOOTPRINT ANALYSIS 167
TABLE 147 PRODUCT FOOTPRINT ANALYSIS (26 COMPANIES) 168
TABLE 148 FUNCTIONALITY FOOTPRINT ANALYSIS (26 COMPANIES) 169
TABLE 149 REGIONAL FOOTPRINT ANALYSIS (26 COMPANIES) 170
12.6 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 171
12.6.1 STARS 171
12.6.2 PERVASIVE PLAYERS 171
12.6.3 EMERGING LEADERS 171
12.6.4 PARTICIPANTS 171
FIGURE 45 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 172
12.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 173
12.7.1 PROGRESSIVE COMPANIES 173
12.7.2 DYNAMIC COMPANIES 173
12.7.3 RESPONSIVE COMPANIES 173
12.7.4 STARTING BLOCKS 173
FIGURE 46 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 174
12.8 COMPETITIVE SCENARIOS AND TRENDS 175
12.8.1 PRODUCT LAUNCHES/ENHANCEMENTS 175
TABLE 150 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, 2020–2023 175
12.8.2 DEALS 176
TABLE 151 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: DEALS, 2020–2023 176
12.8.3 OTHER DEVELOPMENTS 178
TABLE 152 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: OTHER DEVELOPMENTS, 2020–2023 178

ページTOPに戻る

Table of Contents

Summary

The artificial intelligence (AI) in genomics market is anticipated to grow from an estimated USD 0.5 billion in 2023 to USD 2.0 billion in 2028, at a CAGR of 32.3% during the forecast period. The market has a promising growth potential due to the need to accelerate processes and timeline and reduce drug development and discovery, and improving computing power and declining hardware cost among other factors. However, the lack of curated genomic data and data privacy concerns are expected to limit the growth of this market to a certain extent.

“Deep learning: The fastest-growing segment of the artificial intelligence (AI) in genomics market for machine learning, by type“
The deep learning segment is expected to witness the fastest growth in the infection surveillance services market during the forecast. Deep learning methods have dominated computational modeling strategies in genomics, where they are used to address a variety of questions ranging from the understanding of protein binding from DNA sequences, epigenetic modifications, predicting gene expression from epigenetic marks, or predicting the methylation state of single cells. The growing demand for accelerated genome sequencing analysis workflows and the need to improve the function of gene editing tools is expected to propel market growth.

“The genome sequencing segment is anticipated to be the largest artificial intelligence (AI) in genomics market, by functionality, during the forecast period”
Based on functionality, the market is segmented into genome sequencing, gene editing, clinical workflows, and predictive genetic testing & preventive medicine. The genome sequencing segment accounted for the largest share of the artificial intelligence (AI) in genomics market. The large share of this segment can be attributed to the use of AI solutions to identify chromosomal disorders, dysmorphic syndromes, teratogenic disorders, and single-gene disorders.

“Europe accounted for the second-largest share in the artificial intelligence (AI) in genomics market during the forecast period”
Europe accounted for the second-largest share of the artificial intelligence (AI) in genomics market during the forecast period. The major drivers of market growth are the increasing adoption of AI-based tools in genomic research and drug discovery, favorable government initiatives, growing EMR adoption, increasing patient data volume, increasing venture capital funding, rising healthcare expenditure, and growing geriatric population. Moreover, the potential for AI in advancing R&D activities has also attracted attention to this sector.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–40%, Tier 2–35%, and Tier 3–25%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, and Rest of the World–5%

Key players in the Artificial intelligence (AI) in genomics Market
The key players operating in the artificial intelligence (AI) in genomics market include NVIDIA Corporation (US), Microsoft Corporation (US), Google, Inc. (US), Intel Corporation (US), BenevolentAI (UK), SOPHiA GENETICS (Switzerland), Illumina, Inc. (US), Predictive Oncology, Inc. (US), Invitae Corporation (US), Deep Genomics, Inc. (Canada), Fabric Genomics, Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch, Inc. (US), Dante labs (US), Data4Cure (US), PrecisionLife Ltd (UK), Genoox (US), Lifebit (UK), FDNA, Inc. (US), DNAnexus (US), Engine Biosciences (US), Tempus Labs, Inc. (US), Congenica Ltd (England), Emedgene, Inc. (US), and Seragon Pharmaceuticals, Inc. (US).
Research Coverage:
The report analyzes the artificial intelligence (AI) in genomics market and aims at estimating the market size and future growth potential of this market based on various segments such as offering, technology, functionality, application, end user, and region. The report also includes a product portfolio matrix of various artificial intelligence (AI) in genomics products & services available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global artificial intelligence (AI) in genomics market. The report analyzes this market by product & service and end user.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global artificial intelligence (AI) in genomics market
• Market Development: Comprehensive information on the lucrative emerging markets by products & services and end user
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global artificial intelligence (AI) in genomics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global artificial intelligence (AI) in genomics market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets社のHealthcare IT分野での最新刊レポート

本レポートと同じKEY WORD（artificial）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ゲノミクスにおける人工知能市場：提供（ソフトウェア＆サービス）、技術（機械学習）、機能（遺伝子配列、遺伝子編集）、用途（診断、創薬）、エンドユーザー（製薬、病院）別 - 2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets社のHealthcare IT分野での最新刊レポート

本レポートと同じKEY WORD（artificial）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?